.png){kind=spacer}
Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
Companion Products
The CC6-469 monoclonal antibody specifically recognizes Leucine-rich repeat-containing protein 15 (LRRC15). LRRC15 is a single-pass type I transmembrane glycoprotein that is encoded by LRRC15 which belongs to the Leucine-rich repeat (LRR) domain superfamily. LRRC15 is a 581 amino acid protein with 15 extracellular LRRs, a transmembrane region, and a short intracellular tail. LRRC15 is expressed by stromal cells found in the placenta, skin, lymphoid tissues, and by activated fibroblasts in wounds. LRRC15 is also expressed on fibroblasts in solid tumors including those of the breast, lung, head and neck, and pancreas and on cancer cells of mesenchymal origin found in sarcomas, melanomas, and glioblastomas. LRRC15 is involved in cell-to-cell and cell-to-extracellular matrix (ECM) interactions. LRRC15 expression can be highly upregulated by cancer-associated fibroblasts (CAFs) in response to TGF-β that reside in the tumor microenvironment.
Development References (4)
-
Ben-Ami E, Perret R, Huang Y, et al. LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.. Cancers (Basel). 2020; 12(3):757. (Biology). View Reference
-
Dominguez CX, Müller S, Keerthivasan S, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy.. Cancer Discov. 2020; 10(2):232-253. (Biology). View Reference
-
Krishnamurty AT, Shyer JA, Thai M, et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity.. Nature. 2022; 611(7934):148-154. (Biology). View Reference
-
Slemmons KK, Mukherjee S, Meltzer P, Purcell JW, Helman LJ. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies.. Pediatr Blood Cancer. 2021; 68(2):e28771. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.
Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.